In this case, the involvement of JMJD3 is no longer needed, which highlights the existence of non-genomic pathways in the regulation of the BCL2 gene by EZH2, whereas JMJD3 is able to positively regulate BCL2 expression in a genomic way in non-resistant breast cancer cell lines [88]. The gene discussed is BCL2; the disease is breast cancer.